Loading
Gemcitabine plus nab-paclitaxel is the gentler of the two standard chemotherapy backbones for pancreatic cancer, and the base on which most new drugs are being tested.
MPACT (2013): OS 8.5 vs 6.7 months versus gemcitabine alone. Preferred for less fit patients; the control or backbone arm in PANOVA-3 (TTFields), zoldonrasib first-line combinations, and CLDN18.2 and other add-on trials. Gemcitabine monotherapy (1997) was the standard for 14 years before FOLFIRINOX.
Nucleoside analogue (gemcitabine) plus albumin-bound taxane that may deplete stroma and increase gemcitabine delivery.
1.Gemcitabine + nab-paclitaxel slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2013 | First-line metastatic pancreatic adenocarcinoma (nab-paclitaxel label) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
The evidence behind the 2026 approval of Optune Pax for locally advanced disease, the first new approval in that setting in decades, and an unusual case of a survival gain without a progression-free survival gain.
The document that made biomarker testing part of routine pancreatic cancer care in the United States; the 2018 version it built on fixed the second-line chemotherapy sequence still used in most guidelines.
The definitive negative result for first-generation stromal targeting: a biomarker-selected population, a drug that did what it was designed to do to the matrix, and no survival benefit; the stroma ideas on this page start from here.
With FOLFIRINOX this trial defined the two chemotherapy standards for metastatic pancreatic cancer that still apply, and the gemcitabine and nab-paclitaxel backbone is the comparator in most current first-line pancreatic trials.
Query for this drug: (TITLE:"Gemcitabine + nab-paclitaxel" OR ABSTRACT:"Gemcitabine + nab-paclitaxel" OR TITLE:"Gemzar + Abraxane" OR ABSTRACT:"Gemzar + Abraxane") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gemcitabine + nab-paclitaxel, not a curated reading list.
Shares 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC, LAPIS, NEOLAP, Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC.
Shares Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel, Adenosquamous carcinoma of the pancreas, NAPOLI 3, Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026).
Shares Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells, Adenosquamous carcinoma of the pancreas, Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6, Colloid (mucinous non-cystic) carcinoma of the pancreas.
Shares LAPIS, TRYbeCA-1, APACT, CanStem111P.
Shares Metastatic Pancreatic Cancer: ASCO Guideline Update, Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS wild-type pancreatic ductal adenocarcinoma.
Shares MPACT, RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression, KRAS G12C-mutant pancreatic ductal adenocarcinoma, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma.
Shares Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells, Adenosquamous carcinoma of the pancreas, Colloid (mucinous non-cystic) carcinoma of the pancreas, Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma).
Shares Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells, Adenosquamous carcinoma of the pancreas, Colloid (mucinous non-cystic) carcinoma of the pancreas, Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma).